Modification Form for Permit BIO-UWO-0019

Permit Holder: Shun-Cheng (Shawn) Li

Approved Personnel
(Please stroke out any personnel to be removed)

Ran Wei

Marek Galka

Courtney Voss

Gurpreet Dhami

Xuan Cao

Karen Kennedy

Shelly Sandiford

Thamara Dayarathna

Zezhou Wang

Chengjun Li

Additional Personnel
(Please list additional personnel here)

	Please stroke out any approved Biohazards to be removed below	**Write additional Biohazards for approval below. Give the full name - do not appreviate.**
Approved Microorganisms	E-coli. DH5 alpha, BL21	
Approved Primary and Established Cells	Rodent (primary, spleen, B/T cells), Human (established) BJAB, Jurkat, 293 HEK, LG2, Namalwa, Rodent (established), A20, MeT-5A cell line, A-549 human lung cancer cells	
Approved Use of Human Source Material		
Approved Genetic Modifications (Plasmids/Vectors)	pMIG, pGEX-4T3, pRc/CMV, pCDNA3.1+/hygro,pDEST15, pGEX-2T, pGEX-4T2, pFLAG/CMV2	pHM840
Approved Use of Animals	mice, rats	
Approved Biological Toxin(s)	Cholera toxin	

** PLEASE ATTACH A MATERIAL SAFETY DATA SHEET OR EQUIVALENT FOR NEW BIOHAZARDS.*
*** PLEASE ATTACH A BRIEF DESCRIPTION OF THE WORK THAT EXPLAINS THE BIOHAZARDS USED AND HOW THEY WILL BE STORED, USED AND DISPOSED OF..*

As the principal investigator, I have ensured that all of the personnel named on the form have been trained. I will ensure that this project will follow the Western Biosafety Guidelines and Procedures Manual for Containment Level 1 2 Laboratories (and the Level 3 Facilities Manual for Level 3 projects). I will ensure that UWO faculty, staff and students working in my laboratory have an up-to-date Hazard Communication Form, found at http://www.wph.uwo.ca.

Signature of Permit Holder:

Current Classification: 2 **Containment Level for Added Biohazards:**

Date of Last Biohazardous Agents Registry Form: Oct 10, 2007

Date of Last Modification (if applicable): Jan 30, 2009

BioSafety Officer(s):

Chair, Biohazards Subcommittee: **Date:**

NO SUMMARY PROVIDED

addgene

Find this plasmid at: www.addgene.org
Enter "20701" in the search box

Plasmid 20701: pHM840

Gene/insert name:	GFP-NLS-lacZ
Insert size (bp):	4017
Species of gene(s):	Artificial
Vector backbone:	pcDNA3 (Search Vector Database)
Backbone manufacturer:	Invitrogen
Type of vector:	Mammalian expression
Backbone size (bp):	5352
Cloning site 5':	HindIII
Site destroyed during cloning:	No
Cloning site 3':	XbaI
Site destroyed during cloning:	Yes
5' Sequencing primer:	n/a (List of Sequencing Primers)
Bacteria resistance:	Ampicillin
High or low copy:	Unknown
Grow in standard E. coli @ 37C:	Yes
Sequence:	Visit www.addgene.org/20701
Author's Map:	Visit www.addgene.org/20701
Plasmid Provided In:	DH5a
Principal Investigator:	Thomas Stamminger

Comments: Sequence uploaded to AddGene might not be 100% correct - if necessary verify critical areas by sequencing

Article: Mapping of nuclear localization signals by simultaneous fusion to green fluorescent protein and to beta-galactosidase. Sorg G et al. (Biotechniques. 1999 May . 26(5):858-62. Pubmed)

Please acknowledge the principal investigator and cite this article if you use this plasmid in a publication.

Also, please include the text "Addgene plasmid 20701" in your Materials and Methods section. This information allows Addgene to create a link from the plasmid page to your publication.

Please check www.addgene.org/20701 for updated plasmid information and related links.

Page 1 of 2 - Date: 06/10/2010

addgene

Find this plasmid at: www.addgene.org
Enter "20701" in the search box



Please check www.addgene.org/20701 for updated plasmid information and related links.

Page 2 of 2 - Date: 06/10/2010

Modification Form for Permit BIO-UWO-0019

Permit Holder: Shuo-Cheng Li

Approved Personnel
(Please stroke out any personnel to be removed)

~~Haiying Huang~~
Karen ~~Kavin~~ Kennedy
Shelly Sandiford
Thamara Dayarathna
~~Elena Ostrokhovitch~~
Zezhou Wang
Chengjun Li

Additional Personnel
(Please list additional personnel here)

Xuan Cao
Gurpreet Dhami
Courtney Voss
Marek Galka
Ran Wei

	Please stroke out any approved Biohazards to be removed below	Write additional Biohazards for approval below. *
Approved Microorganisms	E-coli, DH5 alpha, BL21	
Approved Cells	Rodent (primary, spleen, B/T cells), Human (established) BJAB, Jurkat, 293 HEK, LG2, Namalwa, Rodent (established), A20, MeT-5A cell line	A-549 human lung cancer cells (ATCC)
Approved Use of Human Source Material		
Approved GMO	pMIG (CMV2), pGEX4T3, pRc/CMV, pCDNA3.1-hygro	

pFLAG/CMV2
pDEST15
pGEX-2T
pGEX-4T2

* *PLEASE ATTACH A MATERIAL SAFETY DATA SHEET OR EQUIVALENT FOR NEW BIOHAZARDS.*
** *PLEASE ATTACH A BRIEF DESCRIPTION OF THE WORK THAT EXPLAINS THE BIOHAZARDS USED AND HOW THEY WILL BE USED.*

Classification: 2

Date of last Biohazardous Agents Registry Form: Oct 10, 2007

Signature of Permit Holder:

BioSafety Officer(s): Jan 30/09

Chair, Biohazards Subcommittee:

Modification Form for Permit BIO-UWO-0019

Permit Holder: Shun-Cheng Li

Approved use of Animals	mice, rats	
Approved Toxin(s)	Cholera toxin	

Plasmid list

- pDEST15
- pGEX-2T
- pGEX-4T2
- pGEX-4T3

} used to express GST fusion proteins in E. coli cells.

- pMIG
- pFLAG/CMV2
- pRc/CMV
- pcDNA3.1(+)/Hygro

} used to express proteins in mammalian cells.

* *PLEASE ATTACH A MATERIAL SAFETY DATA SHEET OR EQUIVALENT FOR NEW BIOHAZARDS.*
** *PLEASE ATTACH A BRIEF DESCRIPTION OF THE WORK THAT EXPLAINS THE BIOHAZARDS USED AND HOW THEY WILL BE USED.*

Classification: 2

Date of last Biohazardous Agents Registry Form: Oct 10, 2007

Signature of Permit Holder: See page 1

BioSafety Officer(s): A Stanley Jan 30/09

Chair, Biohazards Subcommittee: G.M. Kidder

ATCC
The Global Bioresource Center™

Search Catalog
Select a Category
Go
Login Search Options

About Cultures and Products Science Standards Deposit Services Custom Services Product Use Policy

ATCC Advanced Catalog Search » Product Details

Product Description

Before submitting an order you will be asked to read and accept the terms and conditions of ATCC's Material Transfer Agreement or, in certain cases, an MTA specified by the depositing institution.

Customers in Europe, Australia, Canada, China, Hong Kong, India, Japan, Korea, Macau, Mexico, New Zealand, Singapore, and Taiwan, R.O.C. must contact a local distributor for pricing information and to place an order for ATCC cultures and products.

Print this Page

Cell Biology

ATCC® Number: CCL-185™ Order this Item
Designations: A549
Biosafety Level: 1
Medium & Serum: See Propagation
Organism: *Homo sapiens* (human)

Price: $256.00
Depositors: M Lieber
Shipped: frozen
Growth Properties: adherent
Morphology: epithelial
PHOTO

Source: **Organ:** lung
Disease: carcinoma
Cellular Products: keratin
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Related Cell Culture Products

Isolation: **Isolation date:** 1972
Applications: transfection host(technology from amaxa Roche FuGENE® Transfection Reagents)
Reverse Transcript: negative
DNA Profile (STR): Amelogenin: X,Y
CSF1PO: 10,12
D13S317: 11
D16S539: 11,12
D5S818: 11
D7S820: 8,11
THO1: 8,9.3
TPOX: 8,11
vWA: 14
Cytogenetic Analysis: This is a hypotriploid human cell line with the modal chromosome number of 12, occurring in 24% of cells. Cells with 64 (22%), 65, and 67 chromosome counts also occurred at relatively high frequencies; the rate with higher ploidies was low at 0.4%. There were 6 markers present in single copies in all cells. They include der(6)t(1;6)(q11;q27); ?del(6)(p23); del(11)(q21), del(2)(q11), M4 and M5. Most cells had two X and two Y chromosomes. However, one or both Y chromosomes were lost in 40% of 50 cells analyzed. Chromosomes N2 and N6 had single copies per cell; and N12 and N17 usually had 4 copies.
Isoenzymes: G6PD, B
Age: 58 years
Gender: male
Ethnicity: Caucasian
Comments: This line was initiated in 1972 by D.J. Giard, et al. through explant culture of lung carcinomatous tissue from a

Modification Form for Permit BIO-UWO-0019

Permit Holder: Shun-Cheng Li

Approved Personnel
(Please stroke out any personnel to be removed)

Haiming Huang

Kavin Kennedy

Shelly Sandiford

Thamara Dayarathna

Elena Ostrakhovitch

Zezhou Wang

Chengjun Li

Additional Personnel
(Please list additional personnel here)

	Please stroke out any approved Biohazards to be removed below	Write additional Biohazards for approval below. *
Approved Microorganisms	E-coli. DH5 alpha, BL21	
Approved Cells	Rodent (primary, spleen, B/T cells), Human (established) BJAB, Jurkat, 293 HEK, LG2, Namalwa, Rodent (established), A20	MeT-5A cell line
Approved Use of Human Source Material		
Approved GMO	pMIG, cMV2, pGEX4T3, pRc/CMV, pCDNA3.1-hygro	

* *PLEASE ATTACH A MATERIAL SAFETY DATA SHEET OR EQUIVALENT FOR NEW BIOHAZARDS.*
** *PLEASE ATTACH A BRIEF DESCRIPTION OF THE WORK THAT EXPLAINS THE BIOHAZARDS USED AND HOW THEY WILL BE USED.*

Date of last Biohazardous Agents Registry Form Oct 10, 2007

Signature of Permit Holder:

BioSafety Officer(s): Oct 27/08

Chair,Biohazards Subcommittee:

Modification Form for Permit BIO-UWO-0019

Permit Holder: Shun-Cheng Li

Approved use of Animals	mice, rats	
Approved Toxin(s)	Cholera toxin	

MeT-5A cell line (Biosafety Level 2) in from ATCC.
MeT-5A cells will be operated in biosafety level 2 Lab in the culture hood.
MeT-5A cells will be used to study the structure and function of LNX protein for the purpose of scientific research.

* *PLEASE ATTACH A MATERIAL SAFETY DATA SHEET OR EQUIVALENT FOR NEW BIOHAZARDS.*
** *PLEASE ATTACH A BRIEF DESCRIPTION OF THE WORK THAT EXPLAINS THE BIOHAZARDS USED AND HOW THEY WILL BE USED.*

Date of last Biohazardous Agents Registry Form Oct 10, 2007

Signature of Permit Holder:

BioSafety Officer(s):

Chair,Biohazards Subcommittee:

BIO-UWO-0071

THE UNIVERSITY OF WESTERN ONTARIO
BIOHAZARDOUS AGENTS REGISTRY FORM
Revised Biohazards Subcommittee: January, 2007

This form must be completed by each Principal Investigator holding a grant administered by the University of Western Ontario where the use of biohazardous infectious agents are described in the experimental work proposed. The form must also be completed if animal work is proposed involving the use of biohazardous agents or animal carrying zoonotic agents infectious to humans. Containment Levels will be required in accordance with Laboratory Biosafety Guidelines, 3rd edition, 2004, Health Canada (HC) or Containment Standards for Veterinary Facilities, 1st edition 1996, Canadian Food Inspection Agency (CFIA).

Completed forms are to be returned to Occupational Health and Safety (Stevenson-Lawson Building, Room 60) for forward to the Biohazard Subcommittee. For questions regarding this form, please contact the Biosafety Coordinator at extension 81135. If there are changes to the information on this form (excluding grant title and funding agencies) modifications must be completed and sent to Occupational Health and Safety. See website: www.uwo.ca/humanresources

PRINCIPAL INVESTIGATOR Shawn Li
SIGNATURE [signature]
DEPARTMENT Biochemistry
ADDRESS SDRL 107A
PHONE NUMBER x 82910
EMAIL sli@uwo.ca

Location of experimental work to be carried out: Building(s) SDRL Room(s) 108, 112
*For work being performed at Institutions affiliated with the University of Western Ontario, the Safety Officer for the Institution where experiments will take place must sign the form prior to it being sent to Occupational Health and Safety (See Section 12.0, Approvals). For research being done at Lawson Health Research Institute, London Regional Cancer Centre, Child and Parent Research Institute or Robarts Research Institute, University Biosafety Committee members can also sign as the Safety Officer.

TITLE OF GRANT(S): biochemistry and functional characterization of numb-interacting proteins in asymmetric cell division and neurogenesis

PLEASE ATTACH A BRIEF DESCRIPTION OF YOUR WORK, SUCH A THE RESEARCH GRANT SUMMARY(S) THAT EXPLAINS THE BIOHAZARDS USED. PROJECTS SUBMITTED WITHOUT A SUMMARY WILL NOT BE REVIEWED.

FUNDING AGENCY/AGENCIES CIHR.

Names of all personnel working under Principal Investigators supervision in this location:

i) Zezhou Wang
ii) Elena Ospakhovitch
iii) Thanuara Dayarathna
iv) Chenjun Li
v) Shelly Sandiford
vi) Karen Kennedy
vii) Haiming Huang

DESCRIPTION MUST BE ATTACHED TO THIS FORM OR PROJECT WILL NOT BE REVIEWED

1.0 Microorganisms

1.1 Does your work involve the use of microorganisms or biological agents of plant or animal origin (including but not limited to viruses, prions, parasites, bacteria)? ☒ YES ☐ NO
If no, please proceed to Section 2.0

1.2 Please complete the table below:

Name of Biological agent(s)	Is it known to be a human pathogen? YES/NO	Is it known to be an animal pathogen? YES/NO	Is it known to be a zoonotic agent? YES/NO	Maximum quantity to be cultured at one time?
E. coli	☐ Yes ☒ No	☐ Yes ☒ No	☐ Yes ☒ No	200 mL
DH 5α BL21	☐ Yes ☐ No	☐ Yes ☐ No	☐ Yes ☐ No	
	☐ Yes ☐ No	☐ Yes ☐ No	☐ Yes ☐ No	
	☐ Yes ☐ No	☐ Yes ☐ No	☐ Yes ☐ No	
	☐ Yes ☐ No	☐ Yes ☐ No	☐ Yes ☐ No	

1.3 For above named organism(s) or biological agent(s) circle HC or CFIA Containment Level required. (1) 2 3

1.4 Source of microrganism(s) or biological agent(s)? Novagene

2.0 Cell Culture

2.1 Does your work involve the use of cell cultures? ☒ YES ☐ NO
If no, please proceed to Section 3.0

2.2 Please indicate the type of primary cells (ie. derived from fresh tissue) that will be grown in culture in the table below

Cell Type	Is this cell type used in your work?	Source of Primary Cell Culture Tissue
Human	☐ Yes ☒ No	
Rodent	☒ Yes ☐ No	mice spleen B/T cells
Non-human primate	☐ Yes ☒ No	
Other (specify)		

2.3 Please indicate the type of established cells that will be grown in culture in the table below

Cell Type	Is this cell type used in your work?	Specific cell line(s)	Supplier / Source
		BJAB, Jurkat, 293 HEK 6C2	
Human	☒ Yes ☐ No	Namalwa	ATCC
Rodent	☒ Yes ☐ No	Sp2	ATCC
Non-human primate	☐ Yes ☒ No		
Other (specify)	☐ Yes ☒ No		

2.4 For above named cell type(s) circle HC or CFIA containment level required 1 2 3

DESCRIPTION MUST BE ATTACHED TO THIS FORM OR PROJECT WILL NOT BE REVIEWED

3.0 Use of Human Source Materials

3.1 Does your work involve the use of human source materials? ☐YES ☒NO
If no, please proceed to Section 4.0

3.2 Indicate if the following will be used in the laboratory

- Human blood (whole) or other bodily fluids ☐ YES ☐ NO If YES, Specify _____
- Human blood (fraction) or other bodily fluids ☐ YES ☐ NO If YES, Specify _____
- Human organs (unpreserved) ☐ YES ☐ NO If YES, Specify _____
- Human tissues (unpreserved) ☐ YES ☐ NO If YES, Specify _____

3.3 Is human source known to be infected with and infectious agent ☐ YES ☐ NO
If YES , please name infectious agent _____

3.4 For above named materials circle HC or CFIA containment level required. 1 2 3

4.0 Genetically Modified Organisms and Cell lines

4.1 Will genetic modifications be made to the microorganisms, biological agents or cells described in Sections 1.0 and 2.0 ? ☒ YES ☐ NO
If no, please proceed to Section 5.0

4.2 Will genetic sequences from the following be involved:

- HIV ☐ YES ☒ NO
  if YES specify _____
- HTLV 1 or 2 or genes from any CDC class 1 pathogens ☐ YES ☐ NO
  if YES specify _____
- Other human or animal pathogen and or their toxins ☐ YES ☒ NO
  if YES specify _____

4.3 Will intact genetic sequences be used from

- SV 40 Large T antigen ☐ YES ☐ NO If YES specify _____
- Known oncogenes ☐ YES ☒ NO If YES specify _____

4.4 Will a live vector(s) (viral or bacterial) be used for gene transduction ☒ YES ☐ NO
If YES name virus pMIG

4.5 List specific vector(s) to be used pMX2, pGEX4T3, pRc/CMV, pCDNA3.1 hygro (see attachment)

4.6 Will virus be replication defective ☐ YES ☒ NO

4.7 Will virus be infectious to humans or animals ☐ YES ☒ NO

4.8 Will DNA be integrated into [illegible] ☐ YES ☐ NO

5.0 Human Gene Therapy Trials

5.1 Will human clinical trials using the viral vector in 4.0 be conducted? ☐ YES ☒ NO
If no, please proceed to Section 6.0
If YES attach a full description of the make-up of the virus.

5.2 Will virus be able to replicate in the host? ☐ YES ☐ NO

5.3 How will the virus be administered? _____

5.4 Please give the Health Care Facility where the clinical trial will be conducted: _____

5.5 Has human ethics approval been obtained? ☐ YES ☐ NO

6.0 Animal Experiments

6.1 Will any of the agents listed be used in live animals? ☒ YES ☐ NO
If no, please proceed to section 7.0

6.2 Name of animal species to be used mice/rats

6.3 AUS protocol # 2004-058-06

6.4 If using murine cell lines, have they been tested for murine pathogens? ☑ YES ☐ NO

7.0 Use of Animal species with Zoonotic Hazards

7.1 Will any of the following animals or their organs, tissues, lavages or other bodily fluids including blood be used:

- Pound source dogs ☐ YES ☒ NO
- Pound source cats ☐ YES ☒ NO
- Sheep or goats ☐ YES ☒ NO
- Non- Human Primates ☐ YES ☒ NO If YES specify species _____
- Wild caught animals ☐ YES ☒ NO If YES specify species _____
  colony # _____

8.0 Biological Toxins

8.1 Will toxins of biological origin be used? ☐ YES ☒ NO
If no, please proceed to Section 9.0

8.2 If YES, please name the toxin _____

8.3 What is the LD_{50} (specify species) of the toxin _____

DESCRIPTION MUST BE ATTACHED TO THIS FORM OR PROJECT WILL NOT BE REVIEWED

9.0 Import Requirements

9.1 Will the agent be imported? ☒ YES ☐ NO
If no, please proceed to Section 10.0
If yes, country of origin US (via Edmonton lab etc in Canada)

9.2 Has an Import Permit been obtained from HC for human pathogens? ☒ YES ☐ NO

9.3 Has an import permit been obtained from CFIA for animal pathogens? ☐ YES ☐ NO

9.4 Has the import permit been sent to OHS? ☐ YES ☐ NO
If yes, Permit # _____

10.0 Training Requirements for Personnel named on Form

All personnel named on the above form who will be using any of the above named agents are required to attend the following training courses given by OHS

- Biosafety
- Laboratory and Environmental/Waste Management Safety
- WHMIS

As the Principal Investigator, I have ensured that all of the personnel named on the form who will be using any of the biohazardous agents in Sections 1.0 to 9.0 have been trained.

SIGNATURE _____

11.0 Containment Levels

11.1 For the work described in sections 1.0 to 9.0, please circle the highest HC or CFIA Containment Level required. 1 (2) 3

11.2 Has the facility been certified by OHS for this level of containment? ☑ YES ☐ NO

11.3 If yes, please give the date and permit number: Summer 2007
BIO UWO 0019

12.0 Approvals

UWO Biohazard Subcommittee

Signature G.M. Kidder Date 10 Oct. '07

Safety Officer for Institution where experiments will take place

Signature J Stanley Date Oct. 9/07

Safety Officer for University of Western Ontario (if different than above)

Signature _____ Date _____

DESCRIPTION MUST BE ATTACHED TO THIS FORM OR PROJECT WILL NOT BE REVIEWED

Subject: Re: Human cell line, A-549, lung cancer cells from ATCC
From: Shawn Li <sli@uwo.ca>
Date: Sat, 10 Jan 2009 21:00:15 -0800
To: Jennifer Stanley <jstanle2@uwo.ca>

Thanks a lot, Jennifer
Shawn

Web: http://lilab.uwo.ca

On 8-Jan-09, at 11:24 AM, Jennifer Stanley wrote:

> Dr. Li
> I received a PO for this item this morning, it has been approved. I will add it to your current modification. Let me know if you have a problem with this.
> Jennifer

do not scan this page

Material Transfer Request (Order 20533) - MTA Acknowledgment Form

This is NOT a contract or MTA. This form serves as an acknowledgement by a RECIPIENT SCIENTIST of the terms of the Material Transfer Agreements for the transfer of ORIGINAL MATERIAL (described below) from the PROVIDER SCIENTISTS (listed below) to the RECIPIENT SCIENTIST.

Each ORIGINAL MATERIAL being transferred is the property of the PROVIDER (listed below) and is made available through Addgene, a non-profit organization, to the RECIPIENT SCIENTIST as a service to the scientific community.

1. RECIPIENT Organization receiving the ORIGINAL MATERIAL

Organization: University of Western Ontario

2. Transmittal Fee: Each ORIGINAL MATERIAL is distributed by Addgene with a transmittal fee to reimburse Addgene for preparation, handling and distribution costs.

3. ORIGINAL MATERIAL requested on 01/08/2009.

4. Material Transfer Agreements. Addgene, a non-profit organization, will distribute ORIGINAL MATERIAL to RECIPIENT under the following agreements, which are between RECIPIENT and PROVIDER.

UBMTA

The following plasmids are subjected to this MTA:

ORIGINAL MATERIAL	PROVIDER	PROVIDER SCIENTIST
pCMV HDM2(NES-)	Massachusetts Institute of Technology and the Howard Hughes Medical Institute	Tyler Jacks
pCMV MDM-2	Johns Hopkins University and the Howard Hughes Medical Institute	Bert Vogelstein

Attached as EXHIBIT A

5. The PROVIDER and PROVIDER SCIENTIST have agreed to distribute ORIGINAL MATERIAL through Addgene under the Material Transfer Agreements identified above.

6. RECIPIENT SCIENTIST CERTIFICATION.

Scientist's Name: Chengjun Li
Scientist's Phone Number: 5196612111 ext 85648
Scientist's Address:

University Of Western Ontario
c/o Dock 15
Dental Science Building RM 0037
London Ontario N6A 5C1
CANADA

7. Date of Recipient Scientist Certification: 01/08/2009

Chengjun Li, as RECIPIENT SCIENTIST, has read and understood the terms of the Material Transfer Agreements and Addgene's Terms of Purchase for the transfer of ORIGINAL MATERIAL.

RECIPIENT SCIENTIST also acknowledged that any publication by the RECIPIENT SCIENTIST using the ORIGINAL MATERIAL will acknowledge the scientists that have deposited the ORIGINAL MATERIAL at Addgene and cite their papers and any other relevant papers listed on Addgene's website under the ORIGINAL MATERIAL.

If you have any questions, please contact Addgene at mta@addgene.org.